AbbVie, Roche's Venclexta nails confirmatory combo trial in AML after flopping earlier study

Venclexta
Venclexta received an accelerated FDA approval for AML on the condition of performing three confirmatory trials. (AbbVie)

Weeks after AbbVie and Roche's blood cancer med Venclexta flopped a confirmatory trial in acute myeloid leukemia (AML), the partners hoped for a win to keep their med's chances alive. Now, a Venclexta-chemo combo has hit its marks in a second trial, easing concerns the drug's label will take a major hit. 

A combination of Venclexta and chemotherapy azacitidine beat out azacitidine alone at extending AML patients' lives and rates of remission, according to top-line results from the phase 3 Viale-A trial released Monday. 

Data from the study will be reported early, per an independent data monitoring committee's recommendation, and submitted to the FDA and global health authorities, AbbVie said in a release. The companies will unveil the details at a future medical meeting or in a peer-reviewed journal. 

RELATED: AbbVie, Roche's Venclexta endangers AML approval with flopped confirmatory trial 

The Venclexta-azicitidine trial win comes within weeks of another Venclexta combo flopping a confirmatory trial in AML, where the drug received an accelerated FDA approval back in November 2018. 

Suggested Articles

Bayer has withdrawn part of a proposed Roundup settlement after a judge questioned how it's handling potential future claims.

Consensus pegs cabotegravir peak sales at £750 million ($945 million), indicating it can grab about one-third of the current PrEP market.

The CEOs for COVID-19 vaccine partners Pfizer and BioNTech are sounding confident in their program as they gear up for phase 3.